AKAnna Kukhtiak

Anna Kukhtiak

*This is an algorithmically generated author record based on publicly available information.

Anna Kukhtiak has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MALNUTRITION AND TREATMENT OUTCOMES IN OLDER ADULTS AGED 75 AND OVER: A NARRATIVE REVIEW

    by Klaudia Kontek, Bartłomiej Bobrowski, Honorata Derlatka, Jan Drugacz, Olaf Helbig, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Background: Malnutrition in adults aged 75 years and older is a major determinant of morbidity, mortality, and reduced functional independence. Although diagnostic frameworks such as ESPEN and GLIM have improved recognition, malnutrition in this population remains underdiagnosed and undertreated. Aim: To summarize and critically evaluate current evidence (2010–2025) on the association between malnutrition and treatment outcomes in individuals aged 75 years and older, emphasizing diagnostic criteria, prognostic implications, and the effectiveness of nutritional interventions. Methods: A narrative review was conducted using PubMed, Scopus, Web of Science, and Clinical Nutrition databases. Forty-one studies meeting inclusion criteria were analyzed, including randomized controlled trials, cohort studies, meta-analyses, and expert guidelines. Results: Malnutrition in the 75+ population is consistently associated with longer hospitalization, increased postoperative and infectious complications, higher readmission and mortality rates, and poorer quality of life. Diagnostic heterogeneity persists across studies, and GLIM-based definitions yield the strongest prognostic discrimination. Nutritional interventions—particularly early, multidisciplinary approaches combining oral nutritional supplementation, individualized dietetic care, and rehabilitation—improve short-term outcomes but show variable long-term benefits. Conclusions: Malnutrition in advanced old age is a preventable and modifiable predictor of adverse clinical outcomes. Systematic screening, standardized diagnosis using ESPEN and GLIM criteria, and early implementation of comprehensive nutritional care should become integral to geriatric practice. Future research must include large, age-specific interventional trials evaluating long-term effects on survival, functional capacity, and quality of life.

  • COMPARISON OF THE QUALITY OF LIFE OF ADULT PATIENTS UNDERGOING HAEMODIALYSIS AND PERITONEAL DIALYSIS: NARRATIVE REVIEW

    by Julia Marcinkowska, Jan Drugacz, Olaf Helbig, Bartłomiej Bobrowski, Honorata Derlatka, Klaudia Kontek, Anna Kukhtiak, Łukasz Skowron

    Background: Quality of life is a key clinical outcome in adults with end stage kidney disease, as dialysis profoundly affects physical functioning, psychological wellbeing, daily activities, and social participation. Haemodialysis and peritoneal dialysis differ in treatment organization, patient autonomy, and everyday burden, which may translate into distinct quality of life profiles. Existing evidence remains heterogeneous and sometimes contradictory, partly due to methodological variability. Aims: To summarize and critically analyze published studies comparing quality of life in adult patients treated with haemodialysis and peritoneal dialysis, with emphasis on clinical relevance and interpretability of reported outcomes. Methods: A narrative review was conducted using PubMed, Embase, and Google Scholar. Peer reviewed studies published in English or Polish that assessed quality of life with validated instruments such as SF 36, KDQOL, or WHOQOL were included. Comparative observational studies and relevant systematic reviews were analyzed qualitatively. Results: Most studies reported more favourable quality of life outcomes for peritoneal dialysis in selected domains, particularly autonomy, daily functioning, treatment flexibility, and social participation. However, results were domain specific and inconsistent across studies. Psychological outcomes varied, with some reports of higher depressive burden in peritoneal dialysis and lower anxiety in haemodialysis, potentially related to differences in clinical supervision. Quality of life was strongly influenced by clinical status, psychosocial factors, and healthcare organization in addition to dialysis modality. Conclusions: Dialysis modality is associated with differences in quality of life, but no universal advantage of one treatment over the other can be established. Peritoneal dialysis often confers benefits related to independence and daily functioning, while haemodialysis may provide psychological security for some patients. Quality of life should be integrated into individualized modality selection alongside medical, functional, and psychosocial considerations.

  • The impact of electronic cigarettes on the respiratory system: a narrative review

    by Olaf Helbig, Gabriela Ciszek, Bartłomiej Bobrowski, Honorata Derlatka, Jan Drugacz, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Background: The rapidly increasing global prevalence of e-cigarette use, particularly among adolescents and young adults, has raised significant concern regarding their respiratory safety. E-cigarettes generate an aerosol by heating a liquid mixture containing nicotine, propylene glycol, vegetable glycerin, flavorings, and various toxic and potentially carcinogenic compounds such as aldehydes, acrolein, and heavy metals. The respiratory system, being the primary route of exposure, is especially vulnerable to both acute and chronic toxic effects. Aims: This review aims to synthesize and critically evaluate current evidence on the respiratory consequences of e-cigarette use, with a focus on acute and chronic pulmonary effects, underlying cellular and molecular mechanisms of injury, and implications for public health and clinical practice. Methods: A narrative review was conducted following a structured literature search in PubMed, Scopus, Web of Science, and Embase for studies published between 2018 and 2025. The search included the terms “e-cigarette”, “vaping”, “respiratory system”, “lung injury”, “EVALI”, “oxidative stress”, “nicotine”, and “pulmonary disease”. The initial search identified 246 records; after screening and eligibility assessment, 74 studies were included. Priority was given to systematic reviews, meta-analyses, and large-scale observational or experimental studies. Data were synthesized narratively with emphasis on methodological rigor, quality of evidence, and consistency of findings. Results: E-cigarette use was shown to cause both acute and chronic respiratory injury. Acute effects include airway inflammation, oxidative stress, and epithelial barrier disruption, while chronic exposure is linked to persistent inflammation, bronchial remodeling, and increased risk of asthma and chronic obstructive pulmonary disease. The 2019 EVALI outbreak exemplified the acute toxicity potential, particularly from illicit THC-containing products adulterated with vitamin E acetate. Experimental studies confirm mitochondrial dysfunction and DNA damage, indicating genotoxic and pro-carcinogenic mechanisms already in progress. Epidemiological data consistently show higher prevalence of respiratory symptoms and reduced lung function among e-cigarette users compared with non-users, including those who have never smoked combustible cigarettes. However, interpretation must remain cautious due to methodological heterogeneity, self-reported exposure data, and limited long-term follow-up. Conclusions: Current evidence demonstrates that e-cigarettes are not harmless and should be recognized as independent respiratory risk factors. Although they differ from conventional tobacco products, they induce distinct pathophysiological effects mediated by oxidative stress, inflammation, and epithelial dysfunction. The long-term carcinogenic potential remains uncertain because of limited longitudinal data, yet biomarker evidence indicates possible genotoxicity. Persistent research gaps include the long-term impact of novel flavoring agents, standardized exposure assessment, and dose–response relationships. Continuous high-quality longitudinal research and stronger regulatory measures are essential to mitigate health risks and protect vulnerable populations.

  • COMPARISON OF THE EFFECTIVENESS OF THE DASH DIET AND THE MEDITERRANEAN DIET IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: NARRATIVE REVIEW

    by Jan Drugacz, Olaf Helbig, Bartłomiej Bobrowski, Honorata Derlatka, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Łukasz Skowron

    Background: Arterial hypertension remains the most prevalent modifiable cardiovascular risk factor worldwide and a leading contributor to morbidity and mortality. Lifestyle modification, particularly dietary intervention, is universally recommended as first-line therapy in the prevention and management of hypertension. Aims: The aim of this narrative review was to compare the effectiveness of the Dietary Approaches to Stop Hypertension (DASH) diet and the Mediterranean diet in reducing systolic and diastolic blood pressure. Methods: A narrative review of the literature was conducted using PubMed, Google Scholar, and the World Health Organization databases. Publications in English and Polish concerning adult populations were included, encompassing randomized controlled trials, meta-analyses, and systematic reviews evaluating the effects of DASH and Mediterranean dietary patterns on blood pressure. Results: Both dietary patterns were consistently associated with significant reductions in systolic and diastolic blood pressure and improvement of cardiometabolic parameters. Meta-analyses of randomized trials indicate that the DASH diet reduces systolic blood pressure by approximately 3.2–5.2 mmHg and diastolic blood pressure by 2.0–2.6 mmHg. The Mediterranean diet demonstrates more modest but clinically relevant blood pressure reductions, with pooled systolic decreases of approximately 1.4–5.5 mmHg and diastolic decreases of 1.5–2.0 mmHg. Comparative analyses indicate a greater antihypertensive effect of the DASH diet, particularly in sodium-sensitive individuals. The Mediterranean diet provides broader metabolic and anti-inflammatory benefits. However, long-term durability, effects in resistant hypertension, and impact on hard clinical outcomes remain insufficiently studied. Conclusions: Both the DASH and Mediterranean diets represent effective non-pharmacological strategies for systolic and diastolic values reduction and cardiovascular risk modification. However, available evidence indicates that the DASH diet produces a greater magnitude of blood pressure reduction, likely due to its stricter sodium limitation and higher potassium content.

  • THE ROLE OF INCRETIN-BASED THERAPIES IN ALZHEIMER’S DISEASE: FOCUS ON SEMAGLUTIDE - LITERATURE REVIEW

    by Honorata Derlatka, Bartłomiej Bobrowski, Jan Drugacz, Olaf Helbig, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Background: Alzheimer’s disease is increasingly recognized as a disorder with metabolic and inflammatory components linked to insulin resistance and impaired glucose metabolism. Incretin-based therapies, particularly GLP-1 receptor agonists, have emerged as potential disease-modifying candidates due to their neuroprotective and metabolic actions. Aims: To provide a comprehensive and critical synthesis of current evidence on incretin-based therapies with a focus on semaglutide in Alzheimer’s disease, integrating mechanistic, preclinical, and clinical findings, and to identify key research gaps and priorities for future studies. Methods: A narrative evidence-based review was conducted in accordance with PRISMA principles. Literature was searched in PubMed and Google Scholar for English-language publications from February 2023 to June 2025 using the keywords “Alzheimer’s disease,” “semaglutide,” and “GLP-1 receptor agonists.” A total of 439 records were identified; 40 publications were analyzed, and 16 studies met the inclusion criteria for qualitative synthesis (7 preclinical, 5 clinical, and 4 reviews). Results: In preclinical models, semaglutide improved cognition, reduced neuroinflammation and oxidative stress, and attenuated β-amyloid and tau pathology. Early clinical and observational studies indicate potential neuroprotective effects and an acceptable safety profile, although data remain heterogeneous and underpowered. Evidence concerning blood–brain barrier (BBB) penetration, dose - response dynamics, and comparative efficacy versus other GLP-1RAs is still incomplete. Conclusions: Semaglutide represents a biologically plausible and clinically promising candidate for disease modification in Alzheimer’s disease. Confirmation requires long-term, placebo-controlled clinical trials with standardized cognitive and biomarker endpoints, predefined patient stratification by metabolic status and APOE4 genotype, exploration of alternative administration routes, and identification of predictors of therapeutic response.

  • ADVANCES IN THE TREATMENT OF CONGENITAL ESOPHAGEAL ATRESIA – A REVIEW OF SURGICAL TECHNIQUES AND LONG-TERM OUTCOMES

    by Anna Kukhtiak, Jan Drugacz, Bartłomiej Bobrowski, Honorata Derlatka, Olaf Helbig, Klaudia Kontek, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Background: Congenital esophageal atresia (EA) is a rare developmental anomaly characterized by discontinuity of the esophagus, frequently accompanied by a tracheoesophageal fistula. It affects approximately 1 in 2,500 to 4,000 live births and is often associated with other congenital anomalies. Advances in neonatal intensive care, surgical techniques, and postoperative support have markedly improved survival rates, yet long-term morbidity remains substantial. Aims: This review aims to provide a comprehensive and current analysis of surgical strategies for EA repair, critically appraising the available evidence on long-term outcomes and evaluating emerging multidisciplinary management approaches. Methods: A narrative review was conducted using PubMed, Embase, and Google Scholar to identify peer-reviewed articles published in English between 2015 and January 2025. Inclusion criteria encompassed studies on surgical techniques, clinical and functional outcomes, complications, and long-term management of EA. A total of 31 articles, including original research, systematic reviews, and meta-analyses, were selected. Article selection was performed manually by reviewing titles, abstracts, and full texts, with additional studies identified through reference list screening of included articles. Results: Surgical management of EA has progressed from traditional open thoracotomy to thoracoscopic approaches that reduce musculoskeletal morbidity and improve cosmetic outcomes. Primary anastomosis remains standard in short-gap EA, whereas delayed or staged interventions are preferred in long-gap cases. Despite improved survival rates (>90% in high-income settings), long-term complications such as anastomotic strictures, gastroesophageal reflux, dysphagia, and respiratory morbidity remain frequent. Minimally invasive techniques demonstrate comparable safety and efficacy to open repair in selected patients but require advanced surgical expertise. Lifelong multidisciplinary follow-up involving gastroenterology, pulmonology, nutrition, and psychology is essential to improve functional outcomes and quality of life. Conclusions: While survival in EA has markedly improved, the condition remains a lifelong disorder with significant long-term morbidity. The evidence base is limited by the predominance of retrospective studies, heterogeneity in outcome definitions, and variable follow-up durations. Surgical decisions should balance technical feasibility with long-term quality of life, and future research should prioritize standardized outcome measures, multicenter prospective studies, and optimized follow-up protocols.

  • PREHABILITATION IN HEAD AND NECK CANCER: A NARRATIVE REVIEW

    by Bartłomiej Bobrowski, Honorata Derlatka, Jan Drugacz, Olaf Helbig, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Background: Head and neck cancer (HNC) affects approximately 650,000 individuals annually worldwide. Its treatment frequently leads to significant functional impairments, nutritional deficits, and reduced quality of life. Prehabilitation, defined as a set of interventions delivered between diagnosis and the initiation of treatment, aims to optimize patients' physical, nutritional, and psychological condition to improve treatment tolerance and postoperative outcomes. Aim: This review aims to synthesize current evidence on prehabilitation in patients with HNC, with particular emphasis on multimodal programs and physiotherapy-led interventions. It also identifies research gaps and outlines directions for future clinical implementation. Methods: Narrative review with systematic search according to PRISMA principles was conducted using PubMed, Scopus, and Web of Science, covering the period from 2002 to 2024. Twenty nine studies were included, comprising randomized controlled trials, observational studies, and systematic reviews. Interventions were categorized into physical (including physiotherapy and swallowing exercises), nutritional, and psychosocial components. Outcomes assessed included postoperative complications, length of hospital stay, functional status, and quality of life. Results: Multimodal prehabilitation was associated with reduced complication rates, shorter hospital stays (on average by four days), and improved treatment tolerance. Nutritional interventions helped mitigate the risk of malnutrition, while physical therapy contributed to the preservation of swallowing function. Despite the limited number of studies, consistent positive trends were observed across intervention types. The evidence also suggests potential cost savings, estimated at approximately $18,754 per patient [1] . Conclusions: Prehabilitation is a promising strategy to support functional outcomes in patients undergoing treatment for head and neck cancer. Multimodal approaches show the most benefit and should be further developed and integrated into standard care. Further studies are needed to establish standardized protocols, define optimal timing, and identify patient subgroups most likely to benefit.

  • THE ASSOCIATION BETWEEN GASTROESOPHAGEAL REFLUX DISEASE AND CHRONIC HOARSENESS

    by Jan Drugacz, Bartłomiej Bobrowski, Honorata Derlatka, Olaf Helbig, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk, Łukasz Skowron

    Europäische Wissenschaftliche Gesellschaft Home About the Journal Peer Review Editorial Board For Authors Reviewer Recognition Archive Contact Impressum EWG e.V. Elektronische Zeitschriftbibliotek Logo Bielefeld Academic Search Engine Logo Erfolgreich durch internationale Zusammenarbeit LARYNGOLOGY Cite as: Archiv EuroMedica. 2025. 15; 4. DOI 10.35630/2025/15/4.019 Received 25 July 2025; Accepted 30 August 2025; Published 8 September 2025 THE ASSOCIATION BETWEEN GASTROESOPHAGEAL REFLUX DISEASE AND CHRONIC HOARSENESS Jan Drugacz1 email orcid id logo, Bartłomiej Bobrowski2 orcid id logo, Honorata Derlatka3 orcid id logo, Olaf Helbig4 orcid id logo, Klaudia Kontek5 orcid id logo, Anna Kukhtiak6 orcid id logo, Julia Marcinkowska7 orcid id logo, Martyna Radelczuk8 orcid id logo, Łukasz Skowron3 orcid id logo 1Individual medical practice Jan Drugacz, Bielsko-Biała, Poland 2Medical practice Bartosz Bobrowski, Cieszyn, Poland 3Collegium Medicum, Jan Kochanowski University, Kielce, Poland 4Poznan University of Medical Sciences: Poznan, PL 5John Paul II District Hospital in Kolbuszowa, Poland 6Faculty of Medicine, Medical University of Lodz, Lodz, Poland 7Pomeranian Medical University in Szczecin, Poland 8Military Institute of Medicine, Warsaw, Poland download article (pdf) lek.jandrugacz@gmail.com ABSTRACT Aims: Gastroesophageal reflux disease (GERD) is a widespread condition affecting approximately 13 percent of the global population. One of its most common extraesophageal manifestations is chronic hoarseness. This review aims to explore the relationship between GERD and chronic hoarseness, focusing on epidemiology, pathophysiological mechanisms, diagnostic approaches, and treatment outcomes, and to test the hypothesis that the lack of standardized diagnostic criteria for laryngopharyngeal reflux (LPR) significantly influences reported prevalence rates and treatment results. Methods: A comprehensive review of the literature up to 2025 was conducted to assess the association between GERD and chronic hoarseness. The analysis included data on prevalence, diagnostic methodologies such as 24 hour pH impedance monitoring, endoscopy, laryngoscopy, and esophageal manometry, and treatment modalities including pharmacologic, surgical, and behavioral interventions. Results: The prevalence of chronic hoarseness among GERD patients can reach 97 percent, with professional voice users affected more often than the general population. Rates vary widely between studies due to differences in diagnostic criteria and assessment methods. Pathophysiological mechanisms include mucosal injury from gastric acid, inflammatory changes, and neural dysregulation linked to LPR. Diagnostic accuracy is limited by the absence of standardized LPR criteria. Proton pump inhibitors are effective in most erosive cases but less so in non-erosive disease, with up to 40 percent showing inadequate response. Potassium competitive acid blockers provide similar efficacy with improved pharmacokinetics. Adjunctive therapies such as prokinetics, H2 receptor antagonists, baclofen, alginates, and voice therapy can improve outcomes. Laparoscopic fundoplication offers long-term relief in selected patients, and less invasive endoscopic techniques are options for those unsuitable for surgery. Conclusions: GERD-related hoarseness is a clinically significant condition that requires early recognition and targeted management. The hypothesis that a lack of standardized diagnostic criteria for LPR significantly influences prevalence estimates and treatment outcomes is supported by the reviewed evidence. Standardization of diagnostic protocols is essential to improve epidemiological accuracy and guide therapy. Optimal management requires a personalized approach that may combine pharmacological therapy, surgical intervention, and behavioral modifications, supported by multidisciplinary collaboration.

  • DOES REPEATED INFLUENZA VACCINATION ATTENUATE IMMUNOPROTECTION? A SYSTEMATIC REVIEW

    by Łukasz Skowron, Bartłomiej Bobrowski, Honorata Derlatka, Jan Drugacz, Olaf Helbig, Klaudia Kontek, Anna Kukhtiak, Julia Marcinkowska, Martyna Radelczuk

    Background: Annual influenza vaccination is recommended in many countries due to the rapid antigenic drift of circulating strains, particularly influenza A (H3N2). Evidence indicates that vaccine effectiveness may decline after repeated administrations, partly due to antigenic imprinting, although cellular immunity often remains stable or improves. Understanding the long-term immunological impact of repeated vaccination across age groups is essential for optimizing public health strategies. Aim of the study: To evaluate the effect of repeated influenza vaccination on vaccine effectiveness and immunological outcomes in the general population. Material and Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines. Studies published between January 2020 and March 2025 were identified through PubMed, Google Scholar, and ResearchGate using predefined search strings. Eligible studies reported on repeated or annual influenza vaccination in humans and measured humoral or cellular immune outcomes. Risk of bias and methodological quality were assessed using validated tools. Twenty-eight studies met the inclusion criteria. Results: The studies varied in population characteristics, design, and vaccine type, with most using inactivated formulations. Immune responses were assessed mainly through antibody titers, seroconversion rates, and in some cases, cellular immunity markers. Findings were heterogeneous: 10 studies reported a negative effect of repeated vaccination, 11 showed a beneficial effect, and 7 found no significant impact. When reported, effect sizes were generally small to moderate. Statistical significance was inconsistent, and clinical relevance was frequently unclear. Observed effects were influenced by age, immune status, prior vaccination history, and vaccine formulation. Conclusions: While repeated vaccination may attenuate humoral responses in some populations, particularly older adults, cellular immunity tends to remain stable or improve, contributing to sustained protection. Personalized strategies, such as high-dose or adjuvanted vaccines for the elderly, may help offset reduced antibody responses. Limitations of the current evidence include heterogeneity in study design, absence of standardized outcome definitions, inconsistent statistical reporting, and limited long-term follow-up. Future research should incorporate robust bias assessment, standardized immunological endpoints, and age-stratified analyses to clarify mechanisms and optimize vaccination strategies.